Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Ultragenyx Pharmaceutical Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.70, Ultragenyx Pharmaceutical Inc. trades at 2.3x sales. Over the last twelve months it generated about $734M of revenue and a net loss of $532M. It runs a gross margin of 82.9%, an operating margin of -64.1% and a net margin of -71.8%. It shows return on equity of 213.2%, return on invested capital of -52.7% and a free cash flow yield of -26.0%. On the balance sheet: a debt-to-equity ratio of -3.15 and a current ratio of 1.40. Over the past 52 weeks the share price ranged from $12.73 to $39.89, with a beta of 0.32.
Ultragenyx Pharmaceutical Inc. does not currently pay a dividend.
34 Wall Street analyst ratings cover the stock: 21 Buy, 12 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.